Premium
Dabigatran etexilate in a vitamin‐K antagonist non responder patient during Heartware HVAD support
Author(s) -
Baronetto Andrea,
Centofanti Paolo,
Attisani Matteo,
Boffini Massimo,
Ricci Davide,
Simonato Erika,
Rinaldi Mauro
Publication year - 2017
Publication title -
journal of cardiac surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 58
eISSN - 1540-8191
pISSN - 0886-0440
DOI - 10.1111/jocs.13097
Subject(s) - medicine , dabigatran , vitamin k antagonist , ventricular assist device , vitamin k , cardiology , cardiomyopathy , heparin , antagonist , warfarin , heart failure , atrial fibrillation , receptor
Abstract We report a case of a patient supported with a HeartWare left ventricular assist device for idiopathic cardiomyopathy who was resistance to vitamin‐K antagonists three months after implantation. The patient initially started low‐molecular‐weight heparin therapy and then, after the onset of an ischemic stroke, switched to dabigatran etexilate (DE). The patient had progressive recovery of cardiac function for which the device was explanted. No thrombotic or bleeding events occurred during DE therapy.